Header Ads

Breaking News

Top Democrat dropping support for previously bipartisan Senate drug pricing effort


Sen. Ron WydenRonald (Ron) Lee WydenCoronavirus Report: The Hill’s Steve Clemons interviews Sen. Amy Klobuchar Hillicon Valley: Apple’s developer dispute draws lawmaker scrutiny of App Store | GOP senator blocks bill to expand mail-in and early voting | Twitter flags Trump tweet on protesters for including ‘threat of harm’ GOP senator blocks bill to boost mail-in and early voting during pandemic MORE (Ore.), the top Democrat on the Senate Finance Committee, will not co-sponsor an updated version of what had been a bipartisan measure to lower drug prices, as his partnership with Sen. Chuck GrassleyCharles (Chuck) Ernest GrassleyGrassley knocks Trump, Fox News over town hall answer COVID-19 cases rise as Trump brushes off concerns McConnell, Senate confirm Trump’s 200th judicial nominee MORE (R-Iowa) on the issue appeared to fall apart on Monday.

Wyden last year introduced a bipartisan bill to lower drug prices that he negotiated with Grassley, the chairman of the Senate Finance Committee. Grassley is now preparing to introduce an updated version of the bill with relatively minor changes, but Wyden is dropping off as a co-sponsor. 

The move set off a round of finger-pointing on Monday, as the already long odds for a bipartisan breakthrough on drug prices this year appeared to get even longer. 

Grassley said Democrats, led by Senate Minority Leader Charles Schumer (D-N.Y.), were walking away from the negotiations to preserve drug pricing as a campaign issue, while Wyden said Republicans were never really at the table to begin with given that Senate Majority Leader Mitch McConnellAddison (Mitch) Mitchell McConnellProgressives zero in on another House chairman in primary GOP committee chair: ‘It would help’ if Trump would wear a mask occasionally Pelosi: Nationwide mask mandate ‘definitely long overdue’ MORE (R-Ky.) does not support the bill. 

“Unfortunately, over the past couple of months, Democrats have left the negotiating table,” Grassley wrote in a fiery Wall Street Journal op-ed on Monday. “Democratic colleagues tell me this was a decision made by their party’s leadership. I can only assume the Democratic Party would rather use the issue of drug prices as a political hammer in November’s election than work to address it now.” 

Wyden countered in a statement after the op-ed was published by pointing to McConnell. 

“Democrats have not walked away from the table on drug pricing — Republicans never showed up in the first place,” Wyden said. 

Wyden indicated there was no point in him joining the effort and continuing to lend it bipartisan credibility when McConnell had no interest in bringing the bill up for a vote.  

“Unfortunately, McConnell and many other Senate Republicans are too afraid of Big Pharma to join our effort, so there is no reason to expect our bill will receive a vote on the Senate floor,” Wyden said. “Senate Democrats are not interested in aiding Republicans as they play political games and pretend to support lowering prescription drug prices.”

Indeed, Grassley acknowledged in his op-ed that many of his Republican colleagues do not support the bill. 

“Republicans who sit on their hands are throwing the taxpayers we claim to champion under the bus,” he wrote. 

The original Grassley-Wyden bill had a range of measures to lower drug prices, including capping seniors’ out-of-pocket drug costs in Medicare. More controversially, it included an idea from Wyden to limit Medicare drug price increases to the rate of inflation. That provision led many Senate Republicans to object to the bill as including “price controls.”

Notably, the Grassley-Wyden bill did not include Democrats’ main priority on the issue: allowing Medicare to negotiate prices. 

House Democrats passed a bill to do that in December, and many in the party are championing that effort as superior.  

Grassley, though, argued that his bill is a middle ground and most Republicans would never support Medicare negotiation. 

The White House has offered support for the Grassley bill, but has not made a sustained push to win over congressional Republicans on it. 

Grassley called for more support from President TrumpDonald John TrumpIntelligence suggests Russian bounties led to deaths of several US troops in Afghanistan: report Obama called Philonise Floyd before brother’s memorial service: NYT President Trump tries to cover his tracks by attacking the rule of law MORE in his op-ed.

“The president should use his bully pulpit and demand lower drug prices in the next coronavirus bill,” Grassley wrote. 

Wyden on Monday called for a “bipartisan, bicameral discussion” on the path forward on drug prices.

Grassley, Wyden and Speaker Nancy PelosiNancy PelosiBiden’s record-setting tax increases will take your money — and your job GOP committee chair: ‘It would help’ if Trump would wear a mask occasionally Democratic officials, governors push for nationwide mask mandate as administration defends state-by-state approach MORE (D-Calif.) met last month to discuss the path forward on drug prices, according to a source familiar with the meeting. But there had been little progress since then. In the meeting, Pelosi reiterated the Democratic priority of allowing drug price negotiation, the source said. 

Pelosi noted last week at her weekly press conference that Trump during his campaign had supported drug price negotiation, before backing off as president. 

“The president said during the campaign he was going to, ‘Negotiate like crazy,’ ” she said.  “Crazy, that is a good description of his actions throughout. But, ‘negotiate like crazy’ apparently means not negotiate at all. That is the only way you are going to get the prices — the lowered prices.”



Source link

No comments